论文部分内容阅读
过去200年,对于充血性心衰病人的处理,着重于缓解疾病症状。近30年来,注意力集中在阐明心衰时基本的血液动力学异常的病理生理机制,并在强心剂、利尿剂和血管扩张剂等研制方面取得了很大的进展,使绝大多数病人的临床症状得以改善。但是,充血性心衰病人的病死率仍然很高,各种治疗措施尚不能改善病人的长期生存。心衰病人往往死于进行性加重的基础心脏病,但许多病人在无任何血液动力学或功能恶化的迹象中意外猝死。随着改善泵功能的药物治疗不断进展,不仅要使心衰病人感觉较好(心衰治疗中的第一个领域),转移到更重要是使心衰病人延长寿命(心衰治疗中的第二个领域)。
Over the past 200 years, the treatment of patients with congestive heart failure, focusing on alleviating the symptoms of the disease. In the past 30 years, attention has been focused on the elucidation of the pathophysiological mechanism of basic hemodynamic abnormalities in heart failure and great progress has been made in the development of cardiotonics, diuretics and vasodilators so that most patients’ clinical Symptoms are improved. However, the mortality of patients with congestive heart failure is still high, and various treatment measures have not been able to improve the long-term survival of patients. Patients with heart failure often die of underlying heart disease, which is exacerbated, but many patients unexpectedly die without any signs of haemodynamic or functional deterioration. As drug treatments to improve pump function continue to evolve, not only should patients with heart failure feel better (the first area in the treatment of heart failure), it is even more important to extend the lifespan of patients with heart failure Two areas).